SEC For	m 4																
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL		
Section obligat	this box if no lo n 16. Form 4 or ions may contii tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNER Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estima	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person <sup>*</sup> KAWAS LEEN					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Athira Pharma, Inc.</u> [ ATHA ]							elationship o eck all applic	able)	g Perso	10% Ow	vner	
	(F HRA PHAI ORTH CRH	(Middle) , SUITE 104		3. Date of Earliest Transaction (Month/Day/Year) 02/18/2021							below)	give title Other (s below) President & CEO		респу			
(Street) BOTHE	LL W	98011	4	. If Am	endment, I	Date (	of Original Filed (Month/Day/Year)			Line	X Form filed by One Reporting Person Form filed by More than One Reporting			.			
(City) (State) (Zip)													Person				
Date				Transacti	action 2A. Deemed Execution Date			3. Transacti Code (Ins	on Dispose	rities Acquired (A) or ad Of (D) (Instr. 3, 4 an		5. Amount of Securities Beneficially		Form	Direct I Indirect I str. 4)	7. Nature of ndirect Beneficial Ownership (Instr. 4)	
			Table II - De (e.					uired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactio	e Owners 5 Form: Ily Direct (I or Indire 1 (I) (Instr	Ownership	Beneficial Ownership ct (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$21.15	02/18/2021		Α		231,000		(1)	02/17/2031	Common Stock	231,000	\$0.00	231,00	00	D		

Explanation of Responses:

1. One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter.

**Remarks:** 

/s/ Glenna Mileson, Attorney in fact for Leen Kawas 02/21/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.